Peter Emtage on the Combination of MEDI4736 and Tremelimumab for NSCLC

Video

Peter Emtage, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.

Peter Emtage, vice president, immune mediated therapies, MedImmune, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.

These two molecules have different impacts on immune response, Emtage says. Preclinical studies have shown that synergies exist between the two molecules. This combination is being looked at in several indications to determine where these synergies exist.

Researchers saw some exciting and promising activity in this small study, Emtage says. The combination demonstrated an adequate level of tolerability to be studied further.

<<<

View more from the 2014 ESMO Congress

Related Videos
Raj Singh, MD
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology